newsfilter
← Latest News
GlobeNewswire·

LAVA Reports Second Quarter 2024 Financial Results and Business Update

Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for LAVA-1207Next data update for